Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aganirsen for Prevention of Neovascular Glaucoma in iCRVO
NCT02947867Phase 3Unknown
- Sponsor
- Gene Signal International SA
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
Phase 3, randomised, double-blind trial of aganirsen in neovascular glaucoma (NVG) (3 arms), sponsored by Gene Signal International SA. Primary endpoints: Neovascular Glaucoma component at 24 weeks and Intraocular Pressure component at 24 weeks. Status: unknown.
02
Drugs
aganirsen
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT02947867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947867.